To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have B-cell NHL that has persisted or returned despite at least one regimen of standard therapy.
- At least 2 weeks must have passed since completion of prior therapy and entry into the study (12 weeks since monoclonal antibody or radioimmunological therapies).
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is open to patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Craig Moskowitz at 212-639-2696.